The sellside hacks back Lynparza’s prostate opportunity
The writing had been on the wall for Parp inhibitors in first-line prostate cancer, and last week’s US panel showed no mercy.
Medtronic plays catch-up in diabetes
The long-awaited US approval of its newest artificial pancreas comes through, but Medtronic remains behind.
